The purpose of this review is to provide updated information on the role of ghrelin in food intake and energy homeostasis, and on its mechanism of action. Moreover, the potential of ghrelin as a target for drugs to treat cachexia and obesity will be discussed.
Introduction
Ghrelin was identified as an endogenous ligand for the growth hormone secretagogue receptor (GHS-R) type 1a. It is a peptide hormone of 28 amino acids possessing an unusual octanoyl group on the serine in position 3, which is crucial for its biological activity. GHS-R 1a is expressed mainly in the pituitary and hypothalamus. Ghrelin is produced predominantly by the stomach but also by many other tissues such as pituitary, hypothalamus, duodenum, jejunum, ileum, colon, lung, heart, pancreas, kidney and testis. As suggested by its widespread distribution, ghrelin has a wide spectrum of biological activities beyond the stimulation of growth hormone release. Indeed, ghrelin regulates gastric motility, acid secretion, pancreatic secretion, glucose and lipid metabolism, and cell proliferation, and exerts cardiovascular and anti-inflammatory effects. Ghrelin also stimulates appetite and food intake, enhancing fat-mass deposition and body-weight gain. Ghrelin secretion is increased by fasting, inhibited by food intake and increased in response to weight loss. Peripheral factors regulating body weight involve long-term signals indicating body fat stores, and short-term signals indicating immediately available energy. Ghrelin plays an important role in both long-and short-term control of energy balance. The orexigenic effect of ghrelin has been extensively investigated because it may lead to a new therapeutic approach in the treatment of cachexia and obesity.
In this review, we provide an overview of the mechanisms through which ghrelin influences appetite, food intake and energy homeostasis. The use of ghrelin antagonists and agonists as potential therapeutics to respectively treat obesity or wasting conditions is also discussed.
Appetite and food intake: effect of ghrelin on appetite
In rats, intracerebroventricular, intravenous or subcutaneous administration of ghrelin stimulates food intake and decreases energy expenditure, enhancing weight gain [1] . In human, intravenous ghrelin administration also increases appetite and stimulates food intake [2] . Ghrelin is the only known circulating hormone that promotes feeding following systemic administration. Moreover, ghrelin levels increase during fasting, before the onset of meals, and decrease strongly 30 min after feeding, suggesting that ghrelin levels may serve as a signal for meal initiation [3] . In fasting subjects, ghrelin levels display a circadian pattern similar to that described in people eating three times per day [4] .
Mechanisms involved in the effect of ghrelin
Ghrelin stimulates appetite by acting on the hypothalamic arcuate nucleus, a region known to control food intake. The arcuate nucleus contains two neuronal populations involved in control of food intake. The first group contains neurons expressing neuropeptide Y (NPY) and agoutirelated protein (AGRP), which stimulate appetite. The secondgroupcontainsneuronsexpressingpro-opiomelanocortin (POMC), the precursor to a-melanocyte-stimulating hormone (a-MSH) melanocortin, and cocaine-and amphetamine-regulated transcript (CART), which inhibit appetite [5] . Neurons expressing ghrelin have been identified in the arcuate nucleus, and in a previously uncharacterized group of neurons adjacent to the third ventricle between the dorsal, ventral, paraventricular, and arcuate hypothalamic nuclei. These neurons send efferents on to neurons producing NPY, AGRP, POMC, and corticotropin-releasing hormone [6] .
Ghrelin seems to stimulate appetite and food intake through both orexigenic and anorexigenic pathways.
Central orexigenic pathway
Ghrelin stimulates the activity of NPY/AGRP neurons [6] . In rats, intracerebroventricular injection of ghrelin induces a surexpression of NPY and AGRP mRNAs [7] . Inhibition of endogenous NPY and AGRP by anti-NPY and anti-AGRP antibodies, and by antagonists for Y1 and Y5 receptors, abolished ghrelin-induced feeding [1] . Similarly, in NPY-or AGRP-null mice, ghrelin-induced feeding is weakly attenuated, but completely abolished in mice lacking both NPY and AGRP [8] . Ablation of the NPY/ AGRP neurons in mice completely suppresses the feeding response to ghrelin [9] . In NPY neurons, ghrelin interacts with the GHS-R and increases intracellular calcium via mechanisms depending on phospholipase C and adenylate cyclase-protein kinase A pathways [10 ] . In humans, ghrelin increases circulating NPY levels [11] . All these data indicate that ghrelin activates hypothalamic NPY/ AGRP neurons, stimulating the production of NPY and AGRP and therefore increasing food intake.
Intracerebroventricular administration of ghrelin activates not only the arcuate nucleus but also the paraventricular nucleus and the lateral hypothalamus, including in the orexin neurons [12] . Ghrelin activates in-vitro neurons expressing orexins (hypothalamic orexigenic neuropeptides) [13] . Appetite stimulation induced by ghrelin is inhibited in orexin-null mice and attenuated in mice pretreated with an antiorexin antibody [14] .
Peripheral ghrelin increases noradrenaline in the arcuate nucleus and loss of neurons expressing dopamine b-hydroxylase abolishes ghrelin-induced feeding, suggesting that ghrelin stimulates food intake at least in part through the noradrenergic pathway [15] .
Central anorexigenic pathway
Ghrelin may also inhibit POMC neurons, preventing the release of the anorexigenic peptide a-MSH [16] . CART inhibits food intake and is expressed by both vagal afferent and hypothalamic neurons. Ghrelin administration decreases CART expression in rat vagal afferents neurons [17 ] while peripheral ghrelin blockade using a specific antighrelin antibody increases the expression of CART in the hypothalamic paraventricular nucleus [18] .
Although GHS-R mRNA is expressed in the tuberomammilary nucleus, ghrelin does not affect histamine release, and increases food intake in histamine H 1 -receptor-knockout mice. Thus, ghrelin expresses its action in a histamineindependent manner [19] .
Vagal pathway
Ghrelin may also stimulate appetite via the vagus nerve. Detection of the ghrelin receptor in afferent neurons of the rat and human nodose ganglion suggests that the vagus nerve may transmit ghrelin signal from the stomach to the brain [20, 21] . In rats, blockade of the vagal afferent pathway, by vagotomy or perivagal application of an afferent neurotoxin, suppresses ghrelin-induced feeding [22] . In the same way, patients with vagotomy and esophageal or gastric surgery are insensitive to the appetite-stimulatory effect of ghrelin [23] . Thus, through the activation of GHS-R on vagal afferents in the stomach, the signal induced by ghrelin may reach the nucleus of tractus solitarius, which communicates with the hypothalamus to increase food intake. However, intraperitoneal injection of ghrelin stimulates eating in rats with subdiaphragmatic vagal deafferentation, suggesting that the ghrelin signal does not involve vagal afferents [24] .
Energy homeostasis
In addition to its role in short-term regulation of food intake, ghrelin may also play a role in long-term bodyweight regulation.
Plasma ghrelin levels are negatively correlated with BMI. Indeed, plasma ghrelin level is increased in anorexia nervosa and cachexia, and decreased in obesity. Moreover, ghrelin levels fluctuate in a compensatory manner to body-weight variations [25] . Ghrelin levels decrease with weight gain resulting from overfeeding [26] , pregnancy [27] , olanzapine treatment [28] , or high-fat diet [29] . Conversely, weight loss induces an increase of ghrelin levels. This effect is observed with weight loss resulting from food restriction [30 ] and long-term chronic exercise, but not acute exercise [31] , cachectic states induced by anorexia nervosa [25] , severe congestive heart failure [32] , lung cancer [33] , and breast and colon cancer [34] . However, data on ghrelin levels after weight loss induced by gastric-bypass surgery are controversial. Some studies found a decrease [35] [36] [37] [38] , no change [39] [40] [41] or an increase of ghrelin secretion [42] [43] [44] .
In vivo, chronic ghrelin administration induces adiposity [45, 46] . Ghrelin increases body weight not only by stimulating food intake, but also by reducing energy expenditure, decreasing utilization of fat and increasing utilization of carbohydrates [47] . Ghrelin may thus influence adipocyte metabolism. In vitro, ghrelin stimulates differentiation of preadipocytes [48] , inhibits adipocyte apoptosis [49] and antagonizes lipolysis [50] . Chronic central infusion of ghrelin inhibits lipid oxidation and increases lipogenesis and triglyceride uptake in white adipocytes [51 ] . Ghrelin improves also lean body-mass retention [52 ] . In elderly subjects and after diet-induced weight loss, ghrelin levels increase with reduction of fat-free mass, especially skeletal muscle mass, but not with changes in fat mass [30 ,53] .
Ghrelin-null mice suggest a physiological role for ghrelin in energy homeostasis. The phenotype of ghrelin-null mice is similar to that of wild-type mice in terms of size, growth rate, food intake, body composition, reproduction, gross behavior, and tissue pathology [54] . However, young ghrelin-null mice are protected from the weight gain induced by chronic exposure to a high-fat diet. These mice have lower adiposity and higher energy expenditure and locomotor activity. This suggests that ghrelin plays a role in excess dietary fat storage [55] .
In patients with Prader-Willi syndrome (PWS), a genetic disorder characterized by mental retardation and hyperphagia leading to severe obesity, plasma ghrelin levels are higher than in healthy subjects and do not decrease after a meal [56, 57] . Other studies show that ghrelin levels decrease postprandially in adult patients with PWS, but to a lesser extent than in obese and lean subjects [58 ,59] . This lesser postprandial ghrelin suppression may be due to a blunted postprandial response of peptide YY (PYY), an anorexigenic peptide that decreases postprandial ghrelin levels. The low PYY levels could explain partially the high ghrelin levels observed in PWS [58 ] . Interestingly, children (5 years of age and younger) with PWS have normal ghrelin levels. Since these children have not yet developed hyperphagia or excessive obesity, it suggests that ghrelin levels increase with the onset of hyperphagia [60] . Thus, ghrelin may be responsible, at least partially, for the insatiable appetite and the obesity of these patients.
Interaction between ghrelin and leptin
Opposite to ghrelin, leptin, a protein mainly produced by adipose tissue, decreases food intake and increases energy expenditure to maintain the body fat stores. Fasting increases plasma ghrelin levels and decreases plasma leptin levels. Ghrelin expression in stomach cells, and plasma ghrelin levels, are higher in leptin-null mice, also called ob/ob mice, which are hyperphagic and obese, than in healthy mice. However, ablation of ghrelin in ob/ob mice does not improve the obese phenotype, suggesting that the ob/ob phenotype is not a consequence of high ghrelin plasma levels [61] .
After leptin administration, ghrelin concentration and food intake decrease, and energy expenditure increases [62] . Ghrelin and leptin have thus opposite effects on food intake.
Leptin activates POMC neurons, stimulating release of anorexigenic peptides a-MSH and CART, and inhibits NPY/AGRP neurons, preventing release of orexigenic peptides NPY and AGRP [63] . Moreover, inhibition of NPY/AGRP neurons induced by leptin prevents g-aminobutyric acid (GABA) release, leading to activation of POMC neurons. Oppositely, ghrelin activates NPY neurons and increases g-aminobutyric acid release, leading to inhibition of POMC neurons [6] . By activating NPY neurons, ghrelin increases intracellular calcium via mechanisms dependent on both the adenylate cyclase and phospholipase C pathways. Leptin inhibits intracellular calcium increase induced by ghrelin via a phosphoinositide 3-kinase-and phosphodiesterase 3-mediated pathway [10 ] . Therefore, leptin acts on hypothalamic neurons by inhibiting the effects of ghrelin and inverse variations of ghrelin and leptin levels are critical for energy homeostasis regulation.
Potential clinical applications
Given that ghrelin stimulates food intake, ghrelin agonists or antagonists are mainly developed for cachexia treatment and for obesity treatment, respectively. Although patients with cachexia have increased plasma ghrelin levels, reflecting a compensatory response to weight loss, ghrelin administration still improves food intake and weight gain in a rat model of cancer cachexia [52 ] , and in patients with congestive heart failure or chronic obstructive pulmonary disease [64] . In patients with cachexia associated with anorexia nervosa, the effect of ghrelin administration is controversial [65 ] .
Conversely, ghrelin-receptor antagonists, such as [D-Lys-3]growth hormone-releasing peptide-6, decreases food intake in lean mice and obese mice, and reduces weight gain [66, 67] . Other studies show that antisense polyethylene glycol-modified L-oligonucleotides that specifically bind acylated ghrelin (so-called Spiegelmers) also decrease food intake and body weight in diet-induced obese mice [66,68,69 ,70] . The neutralization of circulating ghrelin by these Spiegelmers may be useful to treat diseases associated with high ghrelin levels such as PWS. A third approach for obesity treatment consists in antighrelin vaccine. Ghrelin hapten immunoconjugates lead to the production of antibodies specifically directed Influence of ghrelin De Vriese and Delporte 617 against acylated ghrelin. In rats with strong antighrelin immune responses, body weight gain is reduced with preferential reduction of fat mass compared to lean mass, by decreasing feed efficiency (weight gain per kilocalorie of food) [71 ] .
Consistent with the high constitutive activity of the ghrelin receptor, inverse agonists of the receptor, decreasing this constitutive activity, may be useful for the treatment of obesity [72] . During long fasting, GHS-R expression increases in the hypothalamus, leading to an increase of GHS-R signalling, a higher appetite, and a decrease of energy expenditure. The decrease of the GHS-R constitutive activity by an inverse agonist could increase the sensitivity to anorexigenic hormones like leptin or PYY, and prevent food intake between meals [73] . However, the use of inverse agonists of the GHS-R in obesity treatment needs to be further investigated.
Conclusion
The importance of ghrelin in appetite stimulation and body weight regulation is intensively investigated. The effect of ghrelin on appetite is mediated in hypothalamus through stimulation of NPY, AGRP and orexin release, and inhibition of a-MSH and CART release, and through activation of GHS-R on vagal afferents in the stomach. The effect of ghrelin on body weight is mediated by stimulating food intake, but also by reducing energy expenditure and promoting adiposity. Ghrelin agonists seem useful for treatment of cachexia induced by cancer, congestive heart failure or chronic obstructive pulmonary disease. Ghrelin-receptor antagonists, Spiegelmers and antighrelin vaccine reduce body-weight gain and might be useful for obesity treatment, particularly in PWS. All these clinical applications of ghrelin need further investigation.
